Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals - Wikidata - awgldk - TriplyDB

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

http://www.wikidata.org/entity/Q34639656

about

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder.Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients.Vortioxetine: Clinical Pharmacokinetics and Drug Interactions.Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults.Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo

P2860

Q31044175-ABC686AF-CBBB-4636-BE1F-C9E8F2460B1C Q40366493-BD2BDC5B-9A20-413E-B4C7-2413475E5E71 Q41495600-AF1D1F1F-4BA0-42DB-809A-D659618667B1 Q47692041-A8B006AA-384F-4A0A-8EE8-B1B7F2D7B724 Q47760557-9C1E7CBB-EAF5-4956-B89C-D79AA179FE27 Q58736541-3CB9A13C-BA3F-445E-AD0E-3B0430EF02F8

P2860

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

http://www.wikidata.org/entity/Q34639656

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

@ast

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

@en

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

@nl

type

label

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

@ast

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

@en

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

@nl

prefLabel

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

@ast

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

@en

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

@nl

P1433

Q34639656-127B8E88-CB94-4C3E-8783-3CD13CFEA543

P1476

Q34639656-D69655D5-5842-41EB-948B-2A865E3ABDB9

P2093

Q34639656-5B1F83AF-5104-4A73-89EC-C7F7E323942D

Q34639656-757418D5-E7F0-40CE-81E7-23E1E93A24E6

Q34639656-B162A393-4D9F-4890-BB19-90DF87280821

Q34639656-EFA412FB-A945-4B69-8792-76E622F3E094

P2860

Q34639656-14A56921-4B7F-493A-8263-1EF9BD1B1E25

Q34639656-2836B4F5-2CF8-4889-902C-B962060BE489

Q34639656-28D6A28D-3474-41CC-88D4-F1098C860478

Q34639656-452D2731-5F77-41A6-9E55-A44AB8F22586

Q34639656-61AC002A-47DD-4F17-A47A-11D49A8EC73C

Q34639656-858B0A49-A49E-4E35-9CED-FFB79E9BBF48

Q34639656-8C9D0CD4-6C6E-4F34-85C6-DF9416845AA5

Q34639656-963929E3-7934-4988-B556-C6AC9B04A022

Q34639656-CD86629F-2B0C-434B-9659-B14C1632DCF7

Q34639656-D8E13644-C2B9-4F1D-A764-0E4219228F2B

P304

Q34639656-3DAB1E27-DCE3-412A-B690-A95DB8D0D9C1

P31

Q34639656-0f12e672-b3ca-44c0-ae42-dd925bffa321

Q34639656-D4C2F510-6CB6-433C-8FA5-D1B062E7E8ED

P356

Q34639656-BB624EB7-C753-46EC-A925-44ECF11377FB

P433

Q34639656-EF7D8ADC-ACE0-432D-A96F-AC5F83F9996C

P478

Q34639656-3DC68FF0-EBA9-42C8-A909-A2713ECDDDA0

P577

Q34639656-DCF16E34-C836-49A7-B463-378EFBE1EADF

P5875

Q34639656-914F8FBF-C2EB-45E2-A0EC-570A76D0FAA4

P698

Q34639656-83152F63-76D4-4759-A4DC-41423D15CD83

P932

Q34639656-F8290C04-F2E5-45D6-AF95-956EB482C207

P356

P1433

Basic and Clinical Pharmacology and Toxicology

P1476

Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals

@en

P2093

Grace Chen

http://www.w3.org/2001/XMLSchema#string

Himanshu Naik

http://www.w3.org/2001/XMLSchema#string

Johan Areberg

http://www.w3.org/2001/XMLSchema#string

Kamilla B Petersen

http://www.w3.org/2001/XMLSchema#string

P2860

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

Diagnosing model diagnostics.

The effect of renal failure on hepatic drug clearance.

Emerging evidence of the impact of kidney disease on drug metabolism and transport.

Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant

Current understanding of drug disposition in kidney disease.

Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004.

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

P304

552-559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCPT.12256

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261923791

http://www.w3.org/2001/XMLSchema#string

P698

24766668

http://www.w3.org/2001/XMLSchema#string

P932

4257570

http://www.w3.org/2001/XMLSchema#string